darren cunningham, inflection bio sciences
TRANSCRIPT
2
Overview
1 in 3 will get cancer – many will not survive
***Our mission
develop groundbreaking new treatments for those suffering with cancer
3
Business Model
DISC TARGET HITS LEAD PRE-CLIN IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH
LEAD IND PACKAGE EARLY CLINICAL
PRE-CLINICAL
10-15 YEAR DEVELOPMENT
Value Inflection:
LICENSE IN PARTNER/ EXIT/IPO
4 – 5 YEAR DEVELOPMENT
4
Phase I Value Creation Potential
Phase I Oncology
Exits
$100m - >$300m
5 Spanish National Cancer Research Centre
Collaboration with CNIO - June 2013
Comprising first-in-class agents protected by composition of matter patents
6
Pipeline – Targeted Therapeutics
RESEARCH PRE-CLIN IND PHASE ITARGET
MULTIPLE MYELOMA
NSCLC
IBL-202 (PIM/PI3K)
IBL-300s (PIM/PI3K/mTOR)
HAEM MALIGNANCIESIBL-100s (Pan-PIM)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
B-CELL LYMPHOMAS
Secure Partner after Phase I
Secure Partner at IND
7
PIM Kinase a driver of resistance in AKT/PI3K
1. PIM expression dramatically elevated by PI3K/AKT pathway inhibition
2. PIM mediates feedback loop driving acquired resistance to a number of treatment modalities.
Underpins rationale for co-targeting PI3K and PIM; huge clinical opportunity
8
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
EGFR TKI ResistantMutant K-RasDe novo PI3k activation
Lung cancer leading cause of cancer death (1.6m ww) - NSCLC ~80% = $10bn market by 2020
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s
NSCLC - K-Ras mutated in 15-30%
Downstream activation include PI3K/AKT/mTOR
PIM inhibition shuts down growth in mutant K-Ras NSCLC cell lines
NSCLC - EGFR mutations in ~10% de novo
Cancer recurs (~12mo) with ~10% due to PI3K activation
PIM elevated in EGFR TKI resistant lines
Squamous cc – PIK3CA/ PTEN mutations ~30%
PIM and PI3K inhibitors act synergistically in vitro and in vivo
PIM mediates PI3K/AKT resistance
9
Research Collaboration Network
Network spanning US, EU, Australia NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL,
MCL, CLL, neuroblastoma, breast cancer, mechanistic
Leadership
Darren Cunningham CEO
15 year record in licensing, M&A, IP, fundraising, IR
Amarin, Elan, PWC
B. Comm, M. Acc, FCA
Dr. Michael O’Neill Director R&D22 year drug
discovery and development
Eli Lilly, Almirall, Merck
BA Psychology, PhD
MANAGEMENT ONCOLOGY ADVISORY PANEL
Prof. Josep Tabernero
Director, Vall d’Hebron Institute of Oncology
Led clinical development of PI3K pathway inhibitors
ESMO Executive Board
Prof. Funda Meric-Bernstam
Professor of Surgical Oncology; and
Chair Department
of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center
Dr. Martin Page
30+ years experience in oncology R&D
Previous VP, Global Head of Oncology Res. J&J
Roles with OSI Pharma, Oxford Glycosciences, and Glaxo-Wellcome
Incorporated 2012 Headquartered in Dublin, with base in London 2 full time employees
– Internship program, 3 in 2015– PhD in TCD via Innovation Partnership
6 board members; panel of international scientific advisors
6 CROs (UK, France, China, India) >10 research collaborations (US, Ireland, UK,
Germany, Sweden, Australia) ~€2.2m raised to date (EI, VC and privates)
11
Corporate profile
